Omnicell Welcomes Perry A. Genova, PhD, as Chief Technology Officer
Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced that Perry A. Genova, PhD, will join the Company as Senior Vice President, Chief Technology Officer, effective March 31, 2025.
Omnicell Announces Chief Financial Officer Transition
Omnicell, Inc. (
NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced that Nchacha Etta will be stepping down from his role as Executive Vice President and Chief Financial Officer, effective September 15, 2025 or until a successor is named. Mr. Etta will continue to serve as Executive Vice President and Chief Financial Officer while Omnicell searches for a new Chief Financial Officer and will work to ensure a smooth transition of his role and responsibilities. The Company has commenced a national search for his successor.
3 Healthcare Stocks Skating on Thin IceHealthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 6.3%. This performance is a noticeable divergence from the S&P 500’s 5.1% return.
Astrana Health (ASTH) To Report Earnings Tomorrow: Here Is What To ExpectHealthcare services company Astrana Health
will be reporting results tomorrow afternoon. Here’s what investors should know.
Privia Health (PRVA) Q4 Earnings Report Preview: What To Look ForHealthcare tech company Privia Health Group (
NASDAQ:PRVA)
will be announcing earnings results tomorrow before market open. Here’s what to expect.
Evolent Health (EVH) Q4 Earnings Report Preview: What To Look ForHealthcare solutions company Evolent Health (
NYSE:EVH)
will be reporting results tomorrow after market close. Here’s what to expect.
Waystar (WAY) Reports Q4: Everything You Need To Know Ahead Of EarningsHealthcare technology company Waystar Holding (
NASDAQ:WAY)
will be reporting results tomorrow morning. Here’s what to look for.
Omnicell (NASDAQ:OMCL) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses ExpectationsHealthcare tech company Omnicell (
NASDAQ:OMCL) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 18.6% year on year to $306.9 million. On the other hand, next quarter’s revenue guidance of $260 million was less impressive, coming in 2% below analysts’ estimates. Its non-GAAP profit of $0.60 per share was 2.8% above analysts’ consensus estimates.
Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results
Omnicell, Inc. (
NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its fiscal year and fourth quarter ended December 31, 2024.
Earnings To Watch: Omnicell (OMCL) Reports Q4 Results TomorrowHealthcare tech company Omnicell (
NASDAQ:OMCL)
will be reporting results tomorrow morning. Here’s what to expect.
Omnicell to Release Fourth Quarter and Full Year 2024 Financial Results on February 6, 2025
Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy and nursing care delivery model, will release its financial results for the fourth quarter and full year 2024, before market open on Thursday, February 6, 2025. The Company will host a conference call and webcast to discuss its financial results at 8:30 a.m. ET that same day.
Omnicell to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, announced that it will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 1:30 p.m. PT.
Omnicell Announces OmniSphere
Omnicell, Inc. (Nasdaq:OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced OmniSphere, a next-generation, cloud native, software workflow engine and data platform. This groundbreaking new platform, designed to leverage the full power of a cloud native architecture, seamlessly integrates robotics and smart devices to support more secure, data-driven, medication management across the continuum of care.
Omnicell to Present at the Piper Sandler 36th Annual Healthcare Conference
Omnicell, Inc. (Nasdaq:OMCL), a leader in transforming the pharmacy care delivery model, announced that it will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 2:00 p.m. ET.
Omnicell Announces Pricing of $150 Million Convertible Senior Notes Offering
Omnicell, Inc. (
NASDAQ: OMCL) (“Omnicell”) today announced the pricing of $150.0 million aggregate principal amount of 1.00% Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Omnicell also granted the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $22.5 million aggregate principal amount of notes. The sale of the notes is expected to close on November 22, 2024, subject to customary closing conditions.
Omnicell Announces Proposed Private Placement of $150 Million of Convertible Senior Notes
Omnicell, Inc. (
NASDAQ: OMCL) (“Omnicell”) today announced that it intends to offer, subject to market conditions and other factors, $150.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Omnicell also intends to grant the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $22.5 million aggregate principal amount of notes.
